10-Q: Xilio Therapeutics Reports Q3 2024 Results, Faces Going Concern Uncertainty

Xilio Therapeutics' Q3 2024 report reveals ongoing losses and substantial doubt about its ability to continue as a going concern, despite a recent licensing deal with Gilead.

Summary

• Xilio Therapeutics reported a net loss of $14.02 million for the three months ended September 30, 2024, and a net loss of $45.148 million for the nine months ended September 30, 2024.
• The company's accumulated deficit reached $370.7 million as of September 30, 2024.
• Xilio had cash and cash equivalents of $61.3 million as of September 30, 2024, which is expected to fund operations through the end of the second quarter of 2025.
• The company has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional capital.
• Revenue for the three and nine months ended September 30, 2024 was $2.263 million and $4.620 million respectively, primarily from a license agreement with Gilead.
• Research and development expenses were $10.759 million for the three months ended September 30, 2024, and $32.375 million for the nine months ended September 30, 2024.
• The company is exploring options to raise additional capital, including equity or debt financing, collaborations, partnerships, or licensing transactions.

Sentiment

Score: 3

Explanation: The document expresses significant concerns about the company's financial viability and ability to continue as a going concern, despite some positive developments like the Gilead partnership. The overall tone is cautious and indicates a high level of risk.

Positives

• Xilio generated $2.263 million in license revenue in Q3 2024 and $4.620 million in the first nine months of 2024, primarily from the Gilead agreement.
• The company has a potential $600.7 million in additional contingent payments from Gilead, including a $75 million transition fee and up to $517.5 million in milestones.
• Xilio is actively exploring various options to secure additional capital, including equity, debt, and strategic partnerships.

Negatives

• Xilio reported a net loss of $14.02 million for Q3 2024 and a net loss of $45.148 million for the first nine months of 2024.
• The company's accumulated deficit reached $370.7 million as of September 30, 2024.
• There is substantial doubt about Xilio's ability to continue as a going concern, with current funds expected to last only through the second quarter of 2025.
• The company's recurring losses from operations raise substantial doubt regarding its ability to continue as a going concern.

Risks

• Xilio's recurring losses from operations raise substantial doubt about its ability to continue as a going concern.
• The company may need to implement additional cost reduction strategies if it fails to secure sufficient additional capital.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting and negatively impact the stock price.
• The company's business is highly dependent on the success of its early-stage product candidates.
• Preclinical development is uncertain, and programs may experience delays or never advance to clinical trials.
• Clinical trials may encounter substantial delays, increased costs, or may be terminated or suspended.
• Product candidates may cause undesirable side effects that could delay or prevent regulatory approval.
• The company relies on third-party manufacturers, which poses risks related to supply and regulatory compliance.
• Xilio faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than they do.
• The company relies on in-license agreements for patent rights and may face risks if it fails to comply with obligations under these licenses.

Future Outlook

The company anticipates that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the end of the second quarter of 2025. However, there is substantial doubt about the company's ability to continue as a going concern. Management plans to raise additional capital through various means.

Management Comments

• Management has developed plans to fund operations, which primarily consist of raising additional capital through one or more of the following: additional equity or debt financings; additional collaborations partnerships or licensing transactions; or other sources.
• Management has based its estimate on assumptions that may prove to be wrong, and the Company could exhaust its available capital resources sooner than it anticipates.

Industry Context

The announcement reflects the challenges faced by clinical-stage biotechnology companies, particularly those with high research and development costs and limited revenue streams. The need for additional capital and the uncertainty surrounding clinical trial outcomes are common themes in the industry.

Comparison to Industry Standards

• Many clinical-stage biotech companies face similar challenges regarding funding and clinical trial success, but Xilio's situation is particularly concerning due to the explicit going concern warning.
• The company's reliance on a single CDMO in China is a common practice but introduces supply chain risks that are being scrutinized in the current geopolitical climate.
• The licensing deal with Gilead is a positive development, but the contingent nature of future payments highlights the uncertainty inherent in biotech partnerships.
• Compared to companies with approved products, Xilio's financial position is weaker, as it is entirely dependent on external funding and potential future milestones.
• Companies like Cullinan Oncology and Dragonfly Therapeutics are also developing IL-12 therapies, indicating a competitive landscape for Xilio's XTX301 program.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential delisting from Nasdaq.
• Employees may experience uncertainty due to potential cost reduction strategies and workforce reductions.
• Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
• Creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to report initial Phase 2 data for vilastobart in combination with atezolizumab in approximately 20 patients with MSS CRC in the fourth quarter of 2024 and in a total of approximately 40 patients with MSS CRC in the first quarter of 2025.
• The company plans to report safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1 clinical trial for XTX301 in the fourth quarter of 2024.
• The company will continue to explore options to raise additional capital.

Key Dates

Keywords

Xilio Therapeutics, biotechnology, immuno-oncology, clinical-stage, tumor-activated, XTX101, XTX301, Gilead Sciences, financial results, going concern, capital raise, license agreement, research and development, clinical trials, regulatory approval